Pharma RSS Feed

ATLANTA -- A popular triglyceride-lowering drug that has been taken by millions of Americans failed to prevent heart disease in a big federal study being presented today. The drug, TriCor from Abbott Laboratories, has been used for over a quarter of a century to lower levels of fatty particles... Forbes -...

Read more

March 12 (Bloomberg) -- David Ludwig, director of the obesity program at Children’s Hospital Boston, was against weight-loss surgery for kids, he says, because it ignored the real problem, a “toxic environment” jammed with junk food.He’s since changed his mind.The rate of obesity in... Crain's Chicago Business - Career change may...

Read more

March 12 (Bloomberg) -- Sanofi-Aventis SA and Bristol-Myers Squibb Co. upgraded a warning for the blood thinner Plavix, saying it may not work so well in people with a certain genetic variant as in others.The drug will carry the U.S. Food and Drug Administration’s strictest caution, known as a... Minnapolis Star...

Read more

BioInvent and Human Genome Sciences (HGS) have signed a deal to discover, develop and commercialise therapeutic monolconal antibodies that target antigens discovered by HGS. The deal will initially focus on the development of antibodies for the treatment of inflammation. BioInvent and HGS... FierceBiotech - HGS, BioInvent ink antibody deal ...

Read more

NEW YORK, March 12 (newratings.com) - Analysts at Citigroup downgrade Abbott Laboratories (ABT) from "hold" to "sell." The target price has been raised from $46 to $52.Share Recommend this article to a friendadd ABT to my stocks and get e-mail alerts on Abbott Labs Marketwatch - Abbott leads drugs stocks...

Read more

The cancer-focused biopharmaceutical company priced 9 million shares of its common stock at $9 per share after Nasdaq closed on March 11th. However, AVEO had hoped to reap as much as $105 million from the Boston Business Journal - Aveo Pharma IPO misses pricing targets, dips after opening bell ...

Read more

"Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities, and further expand the team," the company said in a press release. According to Genetix, its proprietary lentiviral technology delivers corrective genes to the patient's own bone... FierceBiotech - Genetix raises $35M to advance gene...

Read more

We're not even halfway through March, and it seems the month has already been marked with an abundance of failed drug studies. On March 1, Swiss drugmaker Actelion (ALIOF) repored its drug Tracleer had failed to help reduce mortality in patients with idiopathic pulmonary fibrosis. Two days later,... BusinessWeek - Pfizer...

Read more

XOMA Ltd. (NASDAQ: XOMA) reports Q4 EPS of $0.01, 4 cents better than the analyst estimate of ($0.03). Revenue for the quarter was $21.6 million, which compares to the estimate of $15.16 million. Related Categories Earnings Stocks Mentioned TradingMarkets - XOMA Reports 2009 and Fourth...

Read more

Drug developer Synta Pharmaceuticals Corp. ended 2009 with a net profit of $79.1 million fueled by deferred revenue from a no-defunct partnership with GlaxoSmithKline. GSK cancelled the partnership following Synta’s halting of a late-stage drug trial last year. The move stemmed from safety... Mass High Tech - Collaboration revenue gives...

Read more

It sounds counterintuitive, but apparently it seems to be the case: A pill is more effective than lotions at getting rid of resistant head lice. That's the finding of a study that compared the common malathion-based treatment lotion against Stromectal -- a pill containing ivermectin, an... BusinessWeek - Merck’s Stromectol Wipes...

Read more

A former Novartis sales rep was awarded more than $579,000 by a federal jury, which decided that she was retaliated against for taking maternity leave; a class action suit involving similar claims is nearing trial. Report More information about formatting options Pharmalot - Novartis Rep Wins Discrimination Suit Over Pregnancy ...

Read more

March 11 (Bloomberg) -- Medco Health Solutions Inc., the second-biggest U.S. manager of drug benefits, is encouraging doctors to use genetic tests to determine whether drugs will work for particular patients -- saving money and reducing harm caused when prescriptions are wrong.Medco, based in... FiercePharma - Medco amps up personalized medicine...

Read more

South San Francisco-based Cytokinetics (NASDAQ: CYTK), which 1 1/2 years ago shifted its focus from cancer drugs to muscle drugs, said it plans to start a Phase II trial for the drug, CK-2017357, sometime between now and July. Lou Gehrig’s Disease, also known as amyotrophic lateral sclerosis... FierceBiotech - Cytokinetics...

Read more

In the wake of two new studies suggesting a link between bisphosphonates and a certain type of bone breakage, the FDA says it's in the midst of reviewing the drugs' safety. So far, the agency hasn't found "a clear connection" between the meds--including Merck's Fosamax; Sanofi-Aventis and... Pharmalot - A Bad Break:...

Read more

If you want to know why people continue to speculate in biotech stocks, just take a look at the stairsteppy last few days of trading in InterMune (ITMN). Last Thursday it was at $15; now it's at $38. And all you have to do to cash in on these moves...

Read more

AstraZeneca is jumping into the branded generics market with a licensing-and-supply deal with India's Torrent Pharmaceuticals. And like other Big Pharma-generics maker arrangements, this deal will marry AstraZeneca's brand name with Torrent's generic products in an effort to boost... Reuters UK - Astra Dives Into Branded Generics Reuters UK - Astra Boosts...

Read more

Massachusetts joins the cadre of states spending funds on antipsychotics for nursing home patients who probably shouldn't be given the drugs at all, the Boston Globe reports. According to data collected by the Centers for Medicare and Medicaid Services, 28 percent of the state's nursing home... PharmaGossip - J&J - Risperdal:...

Read more

(RTTNews) - Biopharmaceutical company AstraZeneca Plc (AZN: News ,AZN.L: News ) on Thursday announced a license and supply deal with Torrent Pharmaceuticals Ltd. for undisclosed financial terms. According to the agreement, India-based Torrent will supply to AstraZeneca a portfolio of... FOXNews.com - AstraZeneca In License, Supply, Pact With Torrent...

Read more

There's more movement in the Teva Pharmaceuticals executive suite. The world's biggest generics maker announced that chairman Eli Hurvitz, who had been on medical leave, is resigning his position to focus on his recovery. So Teva tapped vice chairman Dr. Phillip Frost to serve as chairman of the... Minnapolis Star Tribune...

Read more